Prommune Inc., announces results of a study on its lead products, HeptaVac™ and HISP-P™ for use in pigs with Swine Influenza Virus infections
24 Aug, 2017, 19:49 ET
KANSAS CITY, Mo., Aug. 24, 2017 /PRNewswire/ -- Prommune Inc., a Midwest-based developer of advanced biologics, announced the completion of its third proof of concept study in pigs.
The latest study related to its lead products HeptaVac™, a self-adjuvating peptide vaccine cocktail and HISP-P™, an immunoactivator and molecular adjuvant both for use in pigs with Swine Influenza A Virus infections.
HeptaVac™ was designed to elicit cellular immunity and contains antigenic peptides from the H1N1 influenza virus proteins, two of which represent conserved sequences between the seasonal and pandemic strains. Each antigenic peptide was individually linked to Prommune's molecular adjuvant HISP™ which activates the innate immune system and generates a Th1-biased immune response. HeptaVac™ was delivered intramuscularly and showed a dose response and a statistically significant reduction in the number of lung lesions in pigs infected with the H1N1 strain of the virus compared to the controls.
Another arm of the study compared the efficacy of HeptaVac™ to HISP-P™ delivered intranasally. This part of the study again showed the efficacy of HeptaVac™ but also showed that the immunoactivator HISP-P™ can reduce the viral load in lung lesions in a statistically significant manner in addition to an overall reduction in the number of lesions. Successful intranasal delivery, opens the door for potential use as mucosal vaccines and adjuvants.
Prommune has recently engaged a cGMP manufacturing partner and will be initiating filings to obtain the necessary licenses to market the two products in the US, in the coming weeks. It is also continuing its research and development activities on its pipeline of products for other production animal species and expects to apply for further licenses within the next 12-18 months.
Dr. Sam Al-Murrani, interim CEO added, "There is a considerable need for new therapeutics, prophylactics and adjuvants for veterinary and human medicine applications. Prommune's lead biologics engage and activate the immune system in ways that are different from the ways through which the majority of "classical" vaccines and adjuvants currently work."
Prommune is positioning itself at the forefront of next generation biologics developers with a pipeline of innovative products each designed to fill the need for new modalities to combat existing and emerging zoonotic diseases.
For Further information, please contact Prommune Inc. at:
[email protected] or call toll free 877-426-9009
SOURCE Prommune Inc.
Share this article